AA
ALPS Advisors Portfolio holdings
AUM
$17.3B
This Quarter Return
+0.57%
1 Year Return
+13.43%
3 Year Return
+69.62%
5 Year Return
+161.48%
10 Year Return
+94.79%
AUM
$17.3B
AUM Growth
+$17.3B
(+0.53%)
Cap. Flow
+$346M
Cap. Flow
% of AUM
1.99%
Top 10 Holdings %
Top 10 Hldgs %
59.81%
Holding
1,066
New
76
Increased
462
Reduced
485
Closed
41
Top Buys
| 1 |
Hess Midstream
HESM
|
$100M |
| 2 |
Plains All American Pipeline
PAA
|
$99.4M |
| 3 |
Enterprise Products Partners
EPD
|
$41.5M |
| 4 |
Western Midstream Partners
WES
|
$32.9M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
$28.1M |
Top Sells
Sector Composition
| 1 | Energy | 68.28% |
| 2 | Technology | 4.29% |
| 3 | Financials | 3.4% |
| 4 | Consumer Discretionary | 2.95% |
| 5 | Materials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Regenxbio
RGNX
$451M
| $222K | ﹤0.01% | +27,045 | New | +$222K |
|
1002
Tourmaline Bio
TRML
$601M
| $221K | ﹤0.01% | 13,846 -3,655 | -21% | -$58.4K |
|
|
ZBIO
1003
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $219K | ﹤0.01% | 22,553 -5,579 | -20% | -$54.1K |
|
|
MBX
1004
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $206K | ﹤0.01% | 18,048 -7,986 | -31% | -$91.1K |
|
1005
iTeos Therapeutics
ITOS
| $206K | ﹤0.01% | 20,653 -7,993 | -28% | -$79.7K |
|
1006
Rezolute
RZLT
$619M
| $206K | ﹤0.01% | 46,105 +3,019 | +7% | +$13.5K |
|
1007
Erasca
ERAS
$445M
| $194K | ﹤0.01% | 152,827 -57,456 | -27% | -$73K |
|
1008
Compass Therapeutics
CMPX
$483M
| $194K | ﹤0.01% | +74,597 | New | +$194K |
|
1009
Arcturus Therapeutics
ARCT
$462M
| $190K | ﹤0.01% | 14,619 -5,330 | -27% | -$69.3K |
|
|
BCYC
1010
Bicycle Therapeutics
BCYC
$511M
| $179K | ﹤0.01% | +25,757 | New | +$179K |
|
1011
Prothena Corp
PRTA
$441M
| $176K | ﹤0.01% | 29,028 -8,928 | -24% | -$54.2K |
|
1012
Terns Pharmaceuticals
TERN
$609M
| $176K | ﹤0.01% | +47,156 | New | +$176K |
|
1013
Atea Pharmaceuticals
AVIR
$267M
| $166K | ﹤0.01% | +46,165 | New | +$166K |
|
1014
Astria Therapeutics
ATXS
$349M
| $163K | ﹤0.01% | 30,424 -13,020 | -30% | -$69.8K |
|
|
RC
1015
Ready Capital
RC
$700M
| $162K | ﹤0.01% | 37,002 -1,396 | -4% | -$6.1K |
|
1016
Olema Pharmaceuticals
OLMA
$375M
| $157K | ﹤0.01% | 36,910 -13,574 | -27% | -$57.8K |
|
1017
Gossamer Bio
GOSS
$562M
| $151K | ﹤0.01% | +122,644 | New | +$151K |
|
1018
Vanda Pharmaceuticals
VNDA
$279M
| $150K | ﹤0.01% | 31,759 -10,234 | -24% | -$48.3K |
|
1019
Annexon
ANNX
$226M
| $142K | ﹤0.01% | 59,201 -23,425 | -28% | -$56.2K |
|
1020
Critical Metals Corp
CRML
$611M
| $142K | ﹤0.01% | 39,674 +2,875 | +8% | +$10.3K |
|
|
CMPS
1021
Compass Pathways
CMPS
$424M
| $141K | ﹤0.01% | 50,433 -15,798 | -24% | -$44.2K |
|
1022
Candel Therapeutics
CADL
$318M
| $137K | ﹤0.01% | +27,045 | New | +$137K |
|
1023
SITE Centers
SITC
$644M
| $116K | ﹤0.01% | 10,243 -386 | -4% | -$4.37K |
|
1024
Y-mAbs Therapeutics
YMAB
$388M
| $110K | ﹤0.01% | 24,429 -8,880 | -27% | -$40K |
|
1025
American Battery Technology Co
ABAT
$229M
| $65.8K | ﹤0.01% | 40,638 +10,610 | +35% | +$17.2K |
|